News

Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting

TORONTO and HOUSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF),…

1 year ago

World’s First Observational Trial to Assess Real-World Efficacy of MDMA Treatment

PharmAla, University of Calgary, and Heroic Hearts Canada to partner on a groundbreaking observational trialVANCOUVER, British Columbia, Nov. 09, 2023…

1 year ago

Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage

Policy Updates from Magellan and Two Additional Payors Increase Access for 3.2 Million Covered LivesMALVERN, Pa., Nov. 09, 2023 (GLOBE…

1 year ago

Evoke Pharma Reports Third Quarter 2023 Financial Results

38% Revenue Increase Compared to Q2 2023; 88% Increase Year-Over-Year Seventh Straight Prescription Fill Increase Since Q1 2022 21% Increase…

1 year ago

Third Harmonic Bio Announces Third Quarter 2023 Financial Results

On track to file a U.S. Investigational New Drug (IND) application for THB335 and initiate clinical studies in 1H’24 Strong financial…

1 year ago

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

-- VAX-31, a 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, is the Broadest-Spectrum PCV to Enter the Clinic -- -- Topline…

1 year ago

Inozyme Pharma to Participate in Upcoming Investor Conferences

BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease…

1 year ago

SFA Therapeutics Announces Updated Psoriasis Data for SFA-002, Bridge Financing, and Foundational Patent

SFA-002 Updated Extension Data Showing 92% PASI 50 and 72% PASI 75$4.5 Million Bridge Financing led by North South VenturesComposition…

1 year ago

Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within Island Ambulatory Surgery Center in Brooklyn, New York

Represents first sales by the Company into an ambulatory surgery center Follows successful evaluation by Island Ambulatory Surgery Center’s founder…

1 year ago

Elutia Completes Divestiture of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million

- Company Now Focused on Proprietary Drug-Eluting Biomatrix Platform - SILVER SPRING, Md., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Elutia…

1 year ago